Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
- Conditions
- Primary HypercholesterolemiaMixed Hyperlipidemia
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01012219
Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- University of Ioannina
- Target Recruit Count
- 120
- Registration Number
- NCT01010516
- Locations
- 🇬🇷
University of Ioannina Medical School, Ioannina, Greece
Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels
- Conditions
- HIV InfectionsDyslipidemiaEndothelial Dysfunction
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- University of Hawaii
- Target Recruit Count
- 20
- Registration Number
- NCT00986986
- Locations
- 🇺🇸
University of Hawaii - Hawaii Center for AIDS, Honolulu, Hawaii, United States
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
- Conditions
- Dyslipidemia
- Interventions
- Drug: Placebo to ERN/LRPT
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1152
- Registration Number
- NCT00961636
Psilocybin Cancer Anxiety Study
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 29
- Registration Number
- NCT00957359
- Locations
- 🇺🇸
NYU College of Dentistry Bluestone Center for Clinical Research, New York, New York, United States
MK0524A Bioequivalence Study (0524A-059)
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 188
- Registration Number
- NCT00944645
Role of Prostaglandins on Niacin-Induced Flushing
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 30
- Registration Number
- NCT00930839
- Locations
- 🇺🇸
Eastern Virgnia Medical School, Strelitz Diabetes Center, Norfolk, Virginia, United States
Study to Test GSK256073 in Patients With Dyslipidemia
- Conditions
- DyslipidaemiasDyslipidemias
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00903617
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Niacin and Endothelial Function in Early CKD
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00852969
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 28
- Registration Number
- NCT00796887
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.